Myriad Genetics Faces New Competition in Prostate Cancer Diagnostics
Update: 2025-12-01
Description
Myriad Genetics stocks plummeted by six percent after FDA approved Cleveland Diagnostics IsoPSA, a new prostate cancer diagnostic test, potentially threatening Myriads market position.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
